New drug combo shows promise for Tough-to-Treat prostate cancer

NCT ID NCT06909825

Ongoing Disease control Sponsor: Fusion Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug combination (FPI-2265 and olaparib) in 85 men with advanced prostate cancer that no longer responds to standard hormone therapy. The goal is to see if the treatment can shrink tumors or lower PSA levels by at least 50%. Participants must have tried at least one prior anti-androgen therapy and be in relatively good health.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Show contact details

Locations

Icon Cancer Centre Kurralta Park

Kurralta Park, South Australia, 5037, Australia
Macquarie University Hospital

Macquarie Park, New South Wales, 2113, Australia
Peter MacCallum Cancer Center

Melbourne, Victoria, 3000, Australia
Princess Alexandra Hospital

Woolloongabba, Queensland, 4102, Australia